WT1 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with WT1-specific TCR gene"
- Conditions
- Acute myelogeous lekemia, Myelodysplastic syndrome
- Registration Number
- JPRN-UMIN000017431
- Lead Sponsor
- Mie University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Not provided
1.Having following serious complications # Uncontrolled anigina pectoris, myocardial infarction, or heart failure # Uncontrolled diabetes mellitus or hytertention # Uncontrolled infection # X-ray-proven interstitial pneumonia or pulmonary fibrosis # Autoimmune disease # Bleeding tendency; PT less than 50%, APTT more than 60sec, serum fibrinogen less than 100mg/dL, FDP more than 20ug/mL Thrombosis tendency 2.History of serious hypersensitivity 3.Unctrolled pleural effusion, ascites, or pericardial effusion 4.Uncontrolled CNS metastasis 5.Systemic corticostoroid or immuno-suppressive therapy 6. Inappropriate for WT1 peptide administration, i.e. allergic to the peptide or adjuvant 7.Mental illness or drug dependency affecting informed consent 8.Pregnant, lactating, or possiblly pregnant women, or willing to be pregnant, or willing male partner, except having cryopreseved sperm 9. Lasting less than four weeks from the previous enrollment to clinical trials 11.Inappropriate for study entry judged by an attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety Immune reaction
- Secondary Outcome Measures
Name Time Method